Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1985 1
1992 1
1993 1
1996 2
1997 2
1998 1
1999 1
2000 2
2001 2
2002 1
2003 1
2004 1
2006 3
2007 3
2008 2
2009 1
2011 1
2012 1
2013 2
2014 5
2015 9
2016 8
2017 7
2018 5
2019 6
2020 9
2021 8
2022 9
2023 10
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20GE, 5BAuthor
Page 1
Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Adeleke M, Vickerstaff V, Ambler G, Hunter R, Bunce C, Nathwani N, Barton K; LiGHT Trial Study Group. Gazzard G, et al. Ophthalmology. 2023 Feb;130(2):139-151. doi: 10.1016/j.ophtha.2022.09.009. Epub 2022 Sep 17. Ophthalmology. 2023. PMID: 36122660 Free article. Clinical Trial.
At 6 years, no significant differences were found for the EuroQol EQ-5D 5 Levels, Glaucoma Utility Index, and Glaucoma Quality of Life-15 (P > 0.05 for all). ...
At 6 years, no significant differences were found for the EuroQol EQ-5D 5 Levels, Glaucoma Utility Index, and Glaucoma Quality of Lif …
Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M; LiGHT Trial Study Group. Gazzard G, et al. Lancet. 2019 Apr 13;393(10180):1505-1516. doi: 10.1016/S0140-6736(18)32213-X. Epub 2019 Mar 9. Lancet. 2019. PMID: 30862377 Free PMC article. Clinical Trial.
The primary outcome was health-related quality of life (HRQoL) at 3 years (assessed by EQ-5D). Secondary outcomes were cost and cost-effectiveness, disease-specific HRQoL, clinical effectiveness, and safety. ...FINDINGS: Of 718 patients enrolled, 356 were randomised to the …
The primary outcome was health-related quality of life (HRQoL) at 3 years (assessed by EQ-5D). Secondary outcomes were cost and cost- …
Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Barton K, Wormald R, Morris S, Hunter R, Rubin G, Buszewicz M, Ambler G, Bunce C; LiGHT Trial Study Group. Gazzard G, et al. Br J Ophthalmol. 2018 May;102(5):593-598. doi: 10.1136/bjophthalmol-2017-310877. Epub 2017 Sep 13. Br J Ophthalmol. 2018. PMID: 28903966 Clinical Trial.
The primary outcome measure is health-related quality of life (HRQL) (EQ-5D five-level). Secondary outcomes are treatment pathway cost and cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, Glaucoma Quality of Life, objective measures of pathway effectiven …
The primary outcome measure is health-related quality of life (HRQL) (EQ-5D five-level). Secondary outcomes are treatment pathway cos …
Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Morris S, Buszewicz M. Gazzard G, et al. Health Technol Assess. 2019 Jun;23(31):1-102. doi: 10.3310/hta23310. Health Technol Assess. 2019. PMID: 31264958 Free PMC article. Clinical Trial.
MAIN OUTCOME MEASURES: The primary outcome was HRQoL at 3 years [as measured using the EuroQol-5 Dimensions, five-level version (EQ-5D-5L) questionnaire]. Secondary outcomes were cost and cost-effectiveness, disease-specific HRQoL, clinical effectiveness and safety. ...LIM …
MAIN OUTCOME MEASURES: The primary outcome was HRQoL at 3 years [as measured using the EuroQol-5 Dimensions, five-level version (EQ-5D …
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Moehler M, et al. J Clin Oncol. 2023 Dec 10;41(35):5388-5399. doi: 10.1200/JCO.23.00170. Epub 2023 Sep 15. J Clin Oncol. 2023. PMID: 37713657 Free PMC article. Clinical Trial.
METHODS: In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor PD-L1 expression at a combined positive score (CPS) of 5, health-related quality of life (HRQoL) was assessed using the EQ-5D and Func …
METHODS: In patients (N = 1,581) concurrently randomly assigned 1:1 to nivolumab plus chemotherapy or chemotherapy and in those with tumor P …
Acute rehabilitation following traumatic anterior shoulder dislocation (ARTISAN): pragmatic, multicentre, randomised controlled trial.
Kearney RS, Ellard DR, Parsons H, Haque A, Mason J, Nwankwo H, Bradley H, Drew S, Modi C, Bush H, Torgerson D, Underwood M; The ARTISAN collaborators; ARTISAN collaborators. Kearney RS, et al. BMJ. 2024 Jan 17;384:e076925. doi: 10.1136/bmj-2023-076925. BMJ. 2024. PMID: 38233068 Free PMC article. Clinical Trial.
MAIN OUTCOME MEASURES: The primary outcome was the Oxford shoulder instability score (a single composite measure of shoulder function), measured six months after treatment allocation. Secondary outcomes included the QuickDASH, EQ-5D-5L, and complications. RESULTS: 482 part …
MAIN OUTCOME MEASURES: The primary outcome was the Oxford shoulder instability score (a single composite measure of shoulder function), meas …
A review of the psychometric properties of generic utility measures in multiple sclerosis.
Kuspinar A, Mayo NE. Kuspinar A, et al. Pharmacoeconomics. 2014 Aug;32(8):759-73. doi: 10.1007/s40273-014-0167-5. Pharmacoeconomics. 2014. PMID: 24846760 Review.
RESULTS: The following generic utility measures were identified: the EQ-5D (n = 9)/EQ-5D-5 Level (EQ-5D-5L) (n = 1), followed by the Health Utilities Index Mark 3/2 (HUI2/HUI3) (n = 3), the SF-6D (n = 2), the Assessment of Quality of Life (AQOL) (n = 2), and …
RESULTS: The following generic utility measures were identified: the EQ-5D (n = 9)/EQ-5D-5 Level (EQ-5D-5L) (n = 1), fo …
The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of Myalgic Encephalomyelitis (ME/CFS): A Report from the European Network on ME/CFS (EUROMENE).
Pheby DFH, Araja D, Berkis U, Brenna E, Cullinan J, de Korwin JD, Gitto L, Hughes DA, Hunter RM, Trepel D, Wang-Steverding X. Pheby DFH, et al. Healthcare (Basel). 2020 Apr 7;8(2):88. doi: 10.3390/healthcare8020088. Healthcare (Basel). 2020. PMID: 32272608 Free PMC article. Review.
We recommend using purchasing power parities (PPP) to facilitate international comparisons, and EuroQol-5D as a generic measure of health status and multi-attribute utility instrument to inform future economic evaluations in ME/CFS....
We recommend using purchasing power parities (PPP) to facilitate international comparisons, and EuroQol-5D as a generic measure of he …
An educational review of the statistical issues in analysing utility data for cost-utility analysis.
Hunter RM, Baio G, Butt T, Morris S, Round J, Freemantle N. Hunter RM, et al. Pharmacoeconomics. 2015 Apr;33(4):355-66. doi: 10.1007/s40273-014-0247-6. Pharmacoeconomics. 2015. PMID: 25595871 Review.
We provide a brief description of the most common questionnaire used to calculate patient level utility scores, the EQ-5D, followed by a discussion of other ways to calculate patient level utility scores alongside a trial including other generic measures of health-related …
We provide a brief description of the most common questionnaire used to calculate patient level utility scores, the EQ-5D, followed b …
98 results